Pharmacotherapy for amyotrophic lateral sclerosis: a review of approved and upcoming agents
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder
involving loss of upper and lower motor neurons, with most cases ending in death within 3–5 …
involving loss of upper and lower motor neurons, with most cases ending in death within 3–5 …
The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease marked by
progressive loss of muscle function. It is the most common adult‐onset form of motor neuron …
progressive loss of muscle function. It is the most common adult‐onset form of motor neuron …
[HTML][HTML] New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022
JS Jiang, Y Wang, M Deng - Frontiers in pharmacology, 2022 - frontiersin.org
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that
primarily affects motor neurons in the brain and spinal cord. In the recent past, there have …
primarily affects motor neurons in the brain and spinal cord. In the recent past, there have …
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs
MK Jaiswal - Medicinal Research Reviews, 2019 - Wiley Online Library
Over the past decades, a multitude of experimental drugs have been shown to delay
disease progression in preclinical animal models of amyotrophic lateral sclerosis (ALS) but …
disease progression in preclinical animal models of amyotrophic lateral sclerosis (ALS) but …
Therapeutic development in amyotrophic lateral sclerosis
M Bucchia, A Ramirez, V Parente, C Simone… - Clinical …, 2015 - Elsevier
Purpose Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease in
adults. It is almost invariably lethal within a few years after the onset of symptoms. No …
adults. It is almost invariably lethal within a few years after the onset of symptoms. No …
Improving clinical trial outcomes in amyotrophic lateral sclerosis
Individuals who are diagnosed with amyotrophic lateral sclerosis (ALS) today face the same
historically intransigent problem that has existed since the initial description of the disease in …
historically intransigent problem that has existed since the initial description of the disease in …
Current and emerging treatments for amyotrophic lateral sclerosis
S Zoccolella, A Santamato… - … disease and treatment, 2009 - Taylor & Francis
Background: Amyotrophic lateral sclerosis (ALS) is a relatively rare neurodegenerative
disorder of both upper and lower motoneurons. Currently, the management of ALS is …
disorder of both upper and lower motoneurons. Currently, the management of ALS is …
Amyotrophic lateral sclerosis: recent advances and future therapies
N Nirmalananthan, L Greensmith - Current opinion in neurology, 2005 - journals.lww.com
In the past few years, significant advances have been made in both our understanding of
amyotrophic lateral sclerosis pathogenesis and the development of new therapeutic …
amyotrophic lateral sclerosis pathogenesis and the development of new therapeutic …
ALS drug development: reflections from the past and a way forward
S Aggarwal, M Cudkowicz - Neurotherapeutics, 2008 - Springer
Tremendous advances in our understanding of pathogenesis of amyotrophic lateral
sclerosis (ALS) have provided a rich pipeline of drugs for clinical trialists. At least 32 unique …
sclerosis (ALS) have provided a rich pipeline of drugs for clinical trialists. At least 32 unique …
Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation
Amyotrophic lateral sclerosis (ALS) is a devastating disease caused by degeneration of
motor neurons. As with all major neurodegenerative disorders, development of disease …
motor neurons. As with all major neurodegenerative disorders, development of disease …